β3Gn-T7 Inhibitors

Chemical inhibitors of β3Gn-T7 disrupt its activity through various mechanisms, each targeting different aspects of the glycoprotein biosynthesis pathway. Swainsonine operates by inhibiting Golgi alpha-mannosidase II, an enzyme crucial for the final shaping of N-linked oligosaccharides, which are the substrates for β3Gn-T7. Similarly, kifunensine impedes mannosidase I, preventing the processing of mannose-rich N-glycans essential for β3Gn-T7 function. Both these inhibitors lead to a build-up of misprocessed glycan structures, rendering them unsuitable for subsequent modification by β3Gn-T7. 1-Deoxymannojirimycin follows a parallel path by obstructing mannosidase, essential for the maturation of the correct glycan structures needed by β3Gn-T7 for its activity.

Other inhibitors target the early stages of glycoprotein processing or the availability of necessary substrates. Castanospermine and deoxynojirimycin inhibit glucosidases, responsible for the initial trimming of N-linked glycans, while celgosivir, a prodrug, inhibits alpha-glucosidase I, equally critical for the maturation of N-linked glycans. Salacinol and nojirimycin also target glucosidases, ensuring that the glycoproteins arriving at β3Gn-T7 are inadequately prepared. On the substrate level, fumonisin B1 and miglustat impair the production of glycosphingolipids, the lipid substrates of β3Gn-T7, by inhibiting ceramide synthase and glucosylceramide synthase, respectively. The resulting decrease in glycosphingolipid levels means that β3Gn-T7 encounters a shortage of substrates to act upon. PDMP acts similarly by reducing glycosphingolipid levels through the inhibition of glucosylceramide synthase. Lastly, AMP-DNM directly competes with the natural nucleotide sugar donor of β3Gn-T7, effectively blocking the enzyme's active site and preventing the transfer of sugar moieties to acceptor substrates. Each of these chemicals, by targeting different points of interference, ensures that β3Gn-T7 is unable to perform its normal function of modifying glycoproteins and glycolipids.